Meropenem, CAS number 96036-03-2, is a broad spectrum antibiotic, effective for both gram negative and gram positive bacteria, including pseudonomas. An injectable antibiotic, meropenem was approved for use by the FDA in July of 1996. Developed by Sumitomo Pharmaceuticals, meropenem is marketed by AstraZeneca in the United States with the brand names Merrem and Meronem. Patients allergic to either penicillin or cephalosporin antibiotics should not take meropenem. Meropenem is administered as an injection in a large muscle or added to an intravenous fluid.
Meropenem is potent, and particularly effective in the treatment of infections of the abdomen, such as appendicitis and peritonitis, skin infections and bacterial meningitis. Typical side effects include nausea, vomiting, diarrhea or constipation, and injection site discomfort. Patients who are pregnant or nursing, or who take certain medications, specifically probenecid (Benemid), valproic acid (Depakene or Depakote), and certain vitamins must tell their doctor. If a patient experiences seizures, dizziness or extreme fatigue it is recommended they contact their provider immediately.
A recent case study report from The International Journal of Tuberculosis and Lung Disease reveals a potential treatment for drug resistant tuberculosis through the use of the combination of meropenem with clavulanate. These promising results, published February 8, 2012 ,indicate optimistic possibilities using meropenem as a treatment for a wider variety of bacterial infections then previously thought. LGM Pharma is a provider of the API meropenem for research and development, including client support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.